Search Videos and More
News
Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study
Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancer
News
Years of Research Help Forge a New Path in Hodgkin Lymphoma Treatment
Medical advances tend to unfold slowly over many years, fueled by successive clinical studies that build upon each other and together provide the evidence needed to change patient care.
News
Novel Genomic Screening Tool Enables Precision Reverse-Engineering of Genetic Programming in Cells
Collaborative research led by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center defines a novel approach to understanding how certain proteins called transcription factors determine which genetic programs will drive cell growth and maturation.
News
FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research
FDA decision establishes cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumors
News
AI Learns Genomic “Language” to Advance Cancer Treatment
The human genome is a sequence of Ts, Gs, Cs, and As that is about 3 billion letters long. And, says Bradley Bernstein, MD, PhD, chair of Dana-Farber’s Department of Cancer Biology, “there’s no dictionary or guide for reading it.”
News
Novel Stem Cell Therapy Safely Repairs Irreversible Corneal Damage in Clinical Trial
An expanded phase clinical trial that tested a groundbreaking, experimental stem cell treatment for blinding cornea injuries found the treatment was feasible and safe in 14 patients who were treated and followed for 18 months, and there was a high proportion of complete or partial success.
News
Early Cancer Detection Studies for High-Risk People
A blood test can now detect the presence of 50 different cancers — most of which do not have any other means of screening.
News
Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem Meetings
Dana-Farber Cancer Institute researchers presented key research studies at the 2025 Tandem Meetings, the premier conference in hematopoietic cell transplantation (HCT) and cellular therapy.
News
A Year of Advances in Genitourinary Cancer
Dana-Farber’s genitourinary cancer team is devoted to research that will advance patient care and improve patient’s lives. Recently, that research — all of it years in the making — has paid off with major achievements.
News
What is a Menin Inhibitor?
Menin, a protein located in the nucleus of various human cell types, often functions as a tumor suppressor by inhibiting excessive cell growth and division.
News
Dana-Farber Investigators Pinpoint Keys to Cell Therapy Response for Leukemia
Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell transplant, will successfully move the patient into remission.
News
Study Finds Care After Donor Stem Cell Transplant Can Be Safely Shared Between Transplant Centers and Local Oncologists
Patients undergoing a donor stem-cell transplant for leukemia or other blood-related cancer require months of specialized follow-up care, traditionally delivered at the center where they received their transplant – often a serious challenge for those who live far away.